torsemide ER

Trials studying torsemide ER

• phase1Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemideterminatedn=20
• phase2Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladdercompletedn=24
• phase4Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failurecompletedn=20
• phase3Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactonecompletedn=24
• phase3A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Diseaserecruitingn=30
• phase3A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjectscompletedn=24
• phase3Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjectscompletedn=24
• phase4A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrsterminatedn=5